Most BIOs that complete offerings are getting money to survive and to complete further studies. ZGNX is not at that phase in theirs existence, they will survive, their main drug is already approved. They just need additional funds to market their product. Look back to ACAD. It was approved, offering was successful, and now a stock in the $20s (their price didn't increase overnight). In addition, ZGNX has a broad market, unlike orphan drugs who serve a limited number of patients. PPS increase won't happen overnight...
very convincing argument. And low volume indicates something. But I am a believer is the institutions bid it back up past $3 and we never look back. Obviously, we know the game plan now. I think there were two upgrades, one at $5.50 and the other at $6.00. so I think it will ultimately be the big players who determine what is going to happen.
Institutions were shorting up until today, IMO. I'm happy zgnx is going at this alone, I have full confidence in any company that can convince the FDA to approve Non-tamper hydrocodone. I'm not worried about Zogenix sales ability, this drug will sell itself. It's practically written in to pain management opioid protocol already.